Abstract
Patients with mental illnesses and their families have strong expectations for psychiatric research to find a curative treatment. Nevertheless, diagnosis and treatment methods based on the pathogenesis of mental disorders have yet to be found. Starting from genome analysis research, there is a strong need to identify phenotypes and functional abnormalities that occur at the molecular, cellular, neural circuit, brain, and individual levels of the disease, to comprehensively clarify the pathogenesis, and to develop pathology‐based diagnostics and fundamental therapeutic drug, and knowledge is being accumulated. In order to promote further development, it is essential to establish a patient‐derived bioresource infrastructure with clinical information in order to aggregate genomic information across multiple institutions, departments, and diseases. In Japan, the establishment of integrated center for neurology and psychiatry genomics (iCNPG) is required as an organization to promote the enhancement of medical care and research for neuropsychiatric disorders while adhering to various ethical guidelines, with the aim of (1) consolidating information to take advantage of scale, (2) implementing data science, (3) promoting data sharing, and (4) achieving sustainability.
